Tag Archives: Survival

New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

Posted on March 11, 2012 by wngai

Colorectal cancer is the fourth most common cancer in men and women with nearly 500,000 deaths due to colorectal cancer every year. When detected early at localized stage I, the 5-year survival rate can reach 90%. At this stage, surgical … Continue reading →

Posted in Cancer, Colorectal cancer | Tagged 5-Fluorouracil, Avastin, bevacizumab, camptosar, Cetuximab, Eloxatin, Erbitux, gastrointestinal stromal tumors, GIST, Gleevec, imatanib, Irinotecan, leucovorin, metastatic colorectal cancer, oxaliplatin, regoragenib, sunitinib, Survival, Sutent | Comments Off

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Posted on March 5, 2012 by wngai

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy! An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →

Posted in Cancer, Prostate cancer | Tagged abiraterone, AFFIRM, bicalutamide, cabazitaxel, Casodex, docetaxel, Drogenil, flutamide, Jevtana, MDV3100, Medivation, metastatic castration-resistant prostate, Prostate cancer, Provenge, sipuleucel-T, Survival, Taxotere, Zytiga | Comments Off

A New Agent That Might Change the Lives of Many Cancer Patients

Posted on October 16, 2011 by wngai

This is not only good news for all prostate cancer patients, but is also good news for all cancer patients. The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and … Continue reading →

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer | Tagged abiraterone, advanced prostate cancer, Alpharadin, ALSYMPCA, bone metastases, Cancer, carbitaxel, docetaxel, immunotherapy, Jevtana, Prostate cancer, Provenge, radium-223 chloride, sipuleucel-T, Stage IV cancers, Survival, Taxotere, Zytiga | Comments Off

Cetuximab Increases Survival in Patients with Lung Cancer with High EGFR Expression

Posted on October 16, 2011 by wngai

Good news for patients with non-small-cell lung cancer (NSCLC)! If you have NSCLC, you might like to ask your oncologist to check whether you have high expression of EGFR. Patients with high EGFR expression represented about 25 percent of people … Continue reading →

Posted in Lung Cancer, Non Small Cell Lung Cancer | Tagged Cetuximab, EGFR, Erbitux, FLEX trial, Non small cell lung cancer, NSCLC, Survival | Comments Off

15 Minutes Exercise Improves Survival!

Posted on October 12, 2011 by wngai

We were told by doctors that we need to exercise at least 30 minutes every day to keep our bodies healthy. Now, a new study indicated only 15 minutes a day of moderate-intensity exercise might be enough! The new study … Continue reading →

Posted in Alternative Medicine, Arrhythmia, Cardiovascular disease, Diabetes, Heart attack, Heart failure, High cholesterol, Hypertension, Stroke, VTE | Tagged Cardiovascular disease, Diabetes, Exercise, Survival | Comments Off

New Monoclonal Antibodies Increased Survival in Lung Cancer Patients

Posted on May 30, 2011 by wngai

A new study showed that non-small-cell lung cancer (NSCLC) patients who have high level of Met proteins in their tumor can have their survival increase three-fold by receiving experimental antibody MetMAb in combination with erlotinib (Tarceva). In the trial, 137 previously-treated … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged erlotinib, Met, MetMAb, Monoclonal antibodies, Non small cell lung cancer, NSCLC, progression-free survival, Survival, Tarceva | Comments Off

Another New Cancer Drug Crizotinib Shows Improvement in Survival

Posted on May 29, 2011 by wngai

It looks like a number of new drugs might become available to lung cancer patients in the near future. Results of an early-stage study suggested that nearly two-thirds of patients with late stage non-small-cell lung cancer who received the experimental … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged ALK, anaplastic lymphoma kinase, Crizotinib, Non small cell lung cancer, NSCLC, Survival | Comments Off

New Personalized Medicine Increases Survival in Melanoma Patients

Posted on April 3, 2011 by wngai

Metastatic melanoma is the deadliest and most aggressive from of skin cancer. A person with metastatic melanoma typically has a short life expectancy that is measured in months. The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and … Continue reading →

Posted in Cancer, Melanoma | Tagged BRAF V600 mutation, dacarbazine, DTIC, Genentech, IFN, IL-2, interferon, interleukin-2, Melanoma, Metastatic melanoma, Patient Access Program, progression-free survival, RG7204, Roche, Survival | Comments Off

New Treatment for Colorectal Cancer Patients with Liver Metastases

Posted on April 3, 2011 by wngai

In the past, bevacizumab (Avastin) plus FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin) is the mainstay treatment for colorectal cancer patients with metastases (Stage IV). Even though the response rate of this regimen is impressive, less than 10% of Stage IV colorectal cancer … Continue reading →

Posted in Cancer, Colorectal cancer | Tagged 5-Fluorouracil, Avastin, bevacizumab, chemotherapy, FOLFOX, leucovorin, metastatic colorectal cancer, oxaliplatin, radiofrequency ablation, RFA, Survival | Comments Off

Docetaxel (Taxotere) is Effective in Heavily Pretreated Nasopharyngeal Carcinoma Patients

Posted on March 6, 2011 by wngai

It is well-established that nasopharyngeal carcinoma (NPC) is a chemo-responsive disease. Despite improved outcome with chemo-radiation (platimum-based chemotherapy with radiation), treatment failure continue to be a problem in patients with locally advanced Stage III/IV disease. Now, a new study published … Continue reading →

Posted in Cancer, Nasopharyngeal Cancer | Tagged docetaxel, Eloxatin, Nasopharyngeal carcinoma, oxaliplatin, platimum, quality of life, Survival, Taxotere | Comments Off